https://mindmedicinelaw.com/briefing/doj-faces-scrutiny-over-halt-fentanyl-act-deadline-20260711-21211The Psychedelic Journalen2026-07-11T22:04:44.510510+00:00DOJ Faces Scrutiny Over HALT Fentanyl Act DeadlineHALT Fentanyl Act, DOJ delay, drug scheduling, fentanyl analogues, regulatory clarity, drug policy, research implications, enforcement priorities, controlled substances, policy impacthttps://mindmedicinelaw.com/briefing/comp360-psilocybin-in-depression-clinical-insights-and-implications-20260711-21209The Psychedelic Journalen2026-07-11T22:04:36.506850+00:00COMP360 Psilocybin in Depression: Clinical Insights and ImplicationsCOMP360 psilocybin, treatment-resistant depression, psychedelic therapy, clinical trials, mental health treatment, neuroplasticity, FDA approval, psychiatric research, regulatory implications, ethical considerationshttps://mindmedicinelaw.com/briefing/psychedelics-enhance-reward-responsiveness-in-rats-20260710-21133The Psychedelic Journalen2026-07-11T22:05:01.782478+00:00Psychedelics Enhance Reward Responsiveness in Ratspsychedelics, reward responsiveness, anhedonia, psilocybin, ketamine, 5-HT 2A receptor, preclinical study, psychiatric disorders, clinical trials, neurosciencehttps://mindmedicinelaw.com/briefing/future-drug-targets-for-depression-emerging-therapies-20260710-21144The Psychedelic Journalen2026-07-11T22:04:53.356392+00:00Future Drug Targets for Depression: Emerging Therapiesdepression treatment, precision medicine, rapid-acting therapies, ketamine, clinical trials, pharmacogenomics, personalized medicine, novel antidepressants, NMDA receptor modulators, psychiatric disordershttps://mindmedicinelaw.com/briefing/psychedelic-assisted-psychosexual-therapy-emerging-frontiers-20260710-21118The Psychedelic Journalen2026-07-11T22:04:17.373497+00:00Psychedelic-Assisted Psychosexual Therapy: Emerging Frontierspsychedelic-assisted therapy, psychosexual dysfunction, psilocybin, MDMA, clinical trials, mental health, altered states of consciousness, therapeutic landscapes, policy implications, empathogenic agentshttps://mindmedicinelaw.com/briefing/psychedelic-stocks-clinical-trial-catalysts-and-market-impact-20260710-20739The Psychedelic Journalen2026-07-10T22:04:20.211751+00:00Psychedelic Stocks: Clinical Trial Catalysts and Market Impactpsychedelic stocks, clinical trial catalysts, market dynamics, investor interest, regulatory updates, psychedelic research, mental health treatment, FDA, psilocybin, MDMAhttps://mindmedicinelaw.com/briefing/fda-approvals-and-safety-monitoring-in-psychedelic-therapy-20260710-20897The Psychedelic Journalen2026-07-10T22:04:09.298317+00:00FDA Approvals and Safety Monitoring in Psychedelic TherapyFDA approvals, psychedelic therapy, safety monitoring, clinical trials, regulatory progress, mental health treatment, psilocybin, MDMA, public health, drug policyhttps://mindmedicinelaw.com/briefing/oregon-psilocybin-agency-faces-overhaul-amid-new-federal-bill-20260710-20896The Psychedelic Journalen2026-07-10T22:03:43.670491+00:00Oregon Psilocybin Agency Faces Overhaul Amid New Federal BillOregon psilocybin agency, psychedelics executive order, psilocybin regulation, federal psychedelics policy, mental health treatment, psychedelic research, therapeutic psilocybin, state and federal regulations, psychedelics legislation, psilocybin therapyhttps://mindmedicinelaw.com/briefing/dmt-s-impact-on-human-neural-stem-cells-mechanisms-and-implications-20260709-21099The Psychedelic Journalen2026-07-11T22:04:26.831957+00:00DMT's Impact on Human Neural Stem Cells: Mechanisms and ImplicationsDMT, neural stem cells, neurogenesis, psychedelic research, antidepressant effects, neurotrophins, clinical applications, neural plasticity, mental health treatment, psychedelic therapyhttps://mindmedicinelaw.com/briefing/bayesian-framework-for-well-being-neuroscience-insights-20260709-20663The Psychedelic Journalen2026-07-11T15:04:18.289569+00:00Bayesian Framework for Well-being: Neuroscience Insightsbayesian framework, well-being, psychedelic research, neuroscience, psychological health, predictive regulation, homeostasis, allostasis, affective states, clinical psychologyhttps://mindmedicinelaw.com/briefing/new-protocol-for-iv-ketamine-in-depression-treatment-20260709-20675The Psychedelic Journalen2026-07-11T15:04:09.702964+00:00New Protocol for IV Ketamine in Depression Treatmentintravenous ketamine, treatment-resistant depression, depression treatment, ketamine protocol, patient monitoring, psychiatric carehttps://mindmedicinelaw.com/briefing/new-protocol-for-iv-ketamine-in-depression-treatment-20260709-20677The Psychedelic Journalen2026-07-10T22:04:34.990464+00:00New Protocol for IV Ketamine in Depression Treatmentintravenous ketamine, depression treatment, treatment-resistant depression, ketamine protocol, psychiatric care, clinical trials, patient monitoring, antidepressant therapy, neuroscience, public healthhttps://mindmedicinelaw.com/briefing/esketamine-maintenance-schedules-in-real-world-study-20260709-20678The Psychedelic Journalen2026-07-10T22:04:27.222426+00:00Esketamine Maintenance Schedules in Real-World Studyesketamine, treatment-resistant depression, maintenance schedules, real-world study, clinical trials, neuroscience, antidepressant effects, patient compliance, psychedelic research, mental health treatmenthttps://mindmedicinelaw.com/briefing/addressing-lessebo-effects-in-psychedelic-trials-20260709-20662The Psychedelic Journalen2026-07-10T15:05:06.968232+00:00Addressing Lessebo Effects in Psychedelic Trialspsychedelic trials, lessebo effect, blinding integrity, psychoeducation, therapeutic alliance, expectancy bias, placebo effect, clinical validity, ethical rigor, trial outcomeshttps://mindmedicinelaw.com/briefing/real-world-outcomes-of-esketamine-and-ketamine-for-trd-20260709-20676The Psychedelic Journalen2026-07-10T15:04:45.742740+00:00Real-World Outcomes of Esketamine and Ketamine for TRDesketamine, ketamine, treatment-resistant depression, community clinic, real-world outcomes, NMDA receptor antagonists, clinical efficacy, insurance coverage, long-term effects, TRD treatmenthttps://mindmedicinelaw.com/briefing/ketamine-s-role-in-addiction-treatment-promise-and-perils-20260709-20628The Psychedelic Journalen2026-07-10T15:04:33.828021+00:00Ketamine's Role in Addiction Treatment: Promise and Perilsketamine, addiction treatment, substance use disorders, treatment-resistant depression, neuroplasticity, misuse liability, clinical trials, psychiatric treatmenthttps://mindmedicinelaw.com/briefing/neural-dynamics-in-mbct-for-depression-a-new-framework-20260708-20629The Psychedelic Journalen2026-07-11T15:04:42.105581+00:00Neural Dynamics in MBCT for Depression: A New Frameworkmindfulness-based cognitive therapy, major depressive disorder, complex harmonics decomposition, neural dynamics, fMRI, ruminative thinking, brain flexibility, psychiatric treatment, neuroimaging, mental health interventionshttps://mindmedicinelaw.com/briefing/behavioral-impact-on-rat-eeg-in-psychedelic-drug-studies-20260708-20630The Psychedelic Journalen2026-07-11T15:04:31.392485+00:00Behavioral Impact on Rat EEG in Psychedelic Drug Studiesbehavioral activity, EEG outcomes, psychedelic research, preclinical studies, standardization, neurophysiology, Wistar rats, EEG power spectrum, global functional connectivity, neuroactive substanceshttps://mindmedicinelaw.com/briefing/serotonin-1b-receptor-increases-with-ketamine-and-ect-20260708-20680The Psychedelic Journalen2026-07-10T15:05:19.012689+00:00Serotonin 1B Receptor Increases with Ketamine and ECTserotonin 1B receptor, ketamine, electroconvulsive therapy, major depressive disorder, PET imaging, Bayesian analysis, depression treatmenthttps://mindmedicinelaw.com/briefing/dmt-trials-show-promise-for-anxiety-and-life-satisfaction-20260708-20665The Psychedelic Journalen2026-07-10T15:04:55.844471+00:00DMT Trials Show Promise for Anxiety and Life SatisfactionDMT trials, anxiety improvement, life satisfaction, treatment-resistant depression, psychedelic therapies, clinical trials, public health strategies, quality of life, mental health treatment, psychedelic researchhttps://mindmedicinelaw.com/briefing/texas-advances-ibogaine-research-without-pharma-partner-20260707-20741The Psychedelic Journalen2026-07-10T15:05:34.039940+00:00Texas Advances Ibogaine Research Without Pharma Partneribogaine research, Texas state-funded program, addiction treatment, psychedelic substances, pharmaceutical partnerships, drug policy, clinical trials, substance use disorders, psychoactive compounds, regulatory challengeshttps://mindmedicinelaw.com/briefing/psychotropic-drug-research-challenges-in-germany-regulatory-hurdles-20260706-20030The Psychedelic Journalen2026-07-11T15:05:06.055413+00:00Psychotropic Drug Research Challenges in Germany: Regulatory Hurdlespsychotropic drugs, Germany, regulatory hurdles, platform studies, mental illness complexity, Federal Joint Committee, drug approval process, precision psychiatry, clinical trials, pharmaceutical industryhttps://mindmedicinelaw.com/briefing/intravenous-ketamine-in-psychiatry-efficacy-and-challenges-20260706-20365The Psychedelic Journalen2026-07-11T15:04:57.378372+00:00Intravenous Ketamine in Psychiatry: Efficacy and Challengesintravenous esketamine, treatment-resistant depression, NMDA receptor antagonist, psychiatric treatment, adverse effects, standardized protocols, neuroplasticity, rapid antidepressanthttps://mindmedicinelaw.com/briefing/topical-amitriptyline-ketamine-lidocaine-for-pediatric-pain-20260626-20738The Psychedelic Journalen2026-07-10T22:03:56.506068+00:00Topical Amitriptyline, Ketamine, Lidocaine for Pediatric Paintopical cream, amitriptyline, ketamine, lidocaine, pediatric pain, neuropathic pain, oncology, clinical trials, pain management, psychedelic therapy